Японія - англійська - すりの適正使用協議会 RAD-AR Council, Japan

novartis pharma k.k. - siponimod fumaric acid - pale red tablet, diameter: 6.2 mm, thickness: 2.8 mm

Японія - англійська - すりの適正使用協議会 RAD-AR Council, Japan

novartis pharma k.k. - siponimod fumaric acid - pale yellow tablet, diameter: 6.2 mm, thickness: 2.8 mm

США - англійська - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - siponimod (unii: rr6p8l282i) (siponimod - unii:rr6p8l282i) - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. mayzent is contraindicated in patients who have: - a cyp2c9*3/*3 genotype [see use in specific populations (8.6) and clinical pharmacology (12.5)] - in the last 6 months experienced myocardial infarction, unstable angina, stroke, tia, decompensated heart failure requiring hospitalization, or class iii or iv heart failure - presence of mobitz type ii second-degree, third-degree av block, or sick sinus syndrome, unless patient has a functioning pacemaker [see warnings and precautions (5.4)] pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mayzent during pregnancy. healthcare providers are encouraged to enroll pregnant patients, or pregnant women may register themselves in the mothertobaby pregnancy study in multiple sclerosis by calling

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - siponimod hemifumarate, quantity: 2.024 mg (equivalent: siponimod, qty 2 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; xanthan gum; lactose monohydrate; colloidal anhydrous silica; glycerol dibehenate; polyvinyl alcohol; iron oxide red; lecithin; purified talc; crospovidone; titanium dioxide; iron oxide yellow - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - siponimod hemifumarate, quantity: 0.278 mg (equivalent: siponimod, qty 0.25 mg) - tablet, film coated - excipient ingredients: iron oxide black; titanium dioxide; lactose monohydrate; lecithin; crospovidone; polyvinyl alcohol; purified talc; colloidal anhydrous silica; glycerol dibehenate; microcrystalline cellulose; iron oxide red; xanthan gum - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - siponimod hemifumarate, quantity: 1.112 mg (equivalent: siponimod, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; glycerol dibehenate; colloidal anhydrous silica; titanium dioxide; purified talc; xanthan gum; iron oxide red; polyvinyl alcohol; iron oxide black; lecithin - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms)

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis pharmaceuticals corporation, united states - siponimod - film-coated tablet - 0.25 mg

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis pharmaceuticals corporation, united states - siponimod - film-coated tablet - 2 mg

Саудівська Аравія - англійська - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis pharmaceuticals corporation, united states - siponimod - film-coated tablet - 0.25 mg

Обʼєднані Арабські Емірати - англійська - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

siponimod -